Derek Dostal
Lawyers
Filters
Live Oak Acquisition V $230 million IPO
The units are listed on the Nasdaq Global Market
Rithm Acquisition $230 million SPAC IPO
We advised Rithm Acquisition Corp., a SPAC, on its IPO and NYSE listing
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market
Primo Brands $1.4 billion exchange offers and $3.85 billion financings
The transactions included new notes, the refinancing of a $3.1 billion term loan facility and a new $750 million revolving facility
Textron $500 million notes offering
The investment-grade notes are due 2035
Lennar spinoff of Millrose
We advised the financial advisers on the spinoff transaction
Bacardi $1 billion notes offering
The investment-grade notes are due 2030 and 2035
PAR Technology $115 million convertible senior notes offering
The notes are due 2030
Outlook Therapeutics $20.4 million warrant liability transaction
Certain holders agreed to exercise Outlook Therapeutics warrants at a reduced exercise price while receiving new warrants
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition